An alternative study in an SCLC population selected for patients with tumors that express high levels of cMYC or low TTF1 (for which CLIA certified assays are available) may have yielded a positive outcome and highlights the utility of high-throughput biomarker discovery in the development and subsequent use of novel therapeutics. The gene discussed is TTF1; the disease is small cell lung carcinoma.